Medline Inc.

MDLN Healthcare Medical Instruments & Supplies

Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.

Revenue
+14.1%
Free cash flow
+916.1%
Total debt
−23.7%

Quarter to September 2026, against a year earlier

39.96 0.39 −0.97%
Market cap
$52.3B
P/E
58.4×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
2.25
Beneish M
−2.38
Dividend safety
n/a

Medline Inc. (MDLN) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Medline Inc. (MDLN) trades at a P/B ratio of 1.8×. Over the past ten years it has ranged from 0.0× (December 2025) to 2.1× (February 2026); the current reading is higher than 67% of that period. That is below the Medical Instruments & Supplies industry median of 2.3× and below the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.8× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/B ratio Change
Sep 2026 1.6× (11.46%)
Jun 2026 1.8× (5.94%)
Mar 2026 1.9× 6.78%
Dec 2025 1.8× —
2 more quarters

Against its own ten years

Low 0.0× High 2.1×
Ten-year median 1.7×
Current reading's percentile 67

P/B ratio against peers

Company P/B ratio
COO The Cooper Companies, Inc. compare 1.5×
ALC Alcon compare 1.7×
MDLN Medline Inc. 1.8×
BAX Baxter International Inc. compare 2.0×
BDX Becton, Dickinson and Company compare 2.4×
SOLV Solventum Corporation compare 3.1×
RMD ResMed Inc. compare 5.7×
WST West Pharmaceutical Services, Inc. compare 9.3×
ISRG Intuitive Surgical, Inc. compare 10.1×
Medical Instruments & Supplies industry median 2.3×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on MDLN